On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > REGULATORY
REGULATORY
- MHLW Advisory Committee to Review Sanofi’s VEGF Inhibitor on Feb. 3
January 24, 2017
- PMDA Risk Communication Update for Atarax, Zelboraf
January 23, 2017
- MHLW Asks Pref. Govt to Conduct On-Site Inspections for Pharmacies, Wholesalers: Minister
January 23, 2017
- Correcting Regional Disparities in Generic Use Important for Achieving Govt’s Targets: Health Policy Bureau Chief
January 23, 2017
- Counterfeit Harvoni Likely Entered Distribution before Reaching Pharmacies: MHLW Official
January 23, 2017
- MHLW to Take Prompt Action on Counterfeit Issue: Bureau Chief
January 20, 2017
- Details of Approvals to Be Provided to Prefectures Prior to Unannounced Inspections: MHLW Official
January 20, 2017
- Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution
January 18, 2017
- MHLW to Ponder Additional Gap-Year Price Survey Method That Won’t Cripple Single-Product, Single-Price Efforts: Kanda
January 17, 2017
- MHLW Task Force on “Data Health” to Compile Report by Summer
January 16, 2017
- PMDA Stops Increasing Review Staff, Current Review-Time Targets to Remain Unchanged: Chief Executive
January 16, 2017
- Industry Speculating Tax Hike Will Delay Annual Revision Rollout to 2021
January 13, 2017
- MHLW Panel on AI Use in Healthcare Boots Up
January 13, 2017
- Projection-Based Price Cuts, Instead of Ex-Post Reviews, Mooted for New Quarterly Scheme
January 12, 2017
- MHLW Wants Specific Plan by May for Four-Times Yearly Price Review of Indication-Added Drugs
January 12, 2017
- Chuikyo Industry, Doctor Reps in Discord over Scope of Price Review for Indication Expansions
January 12, 2017
- Revlimid Ordered to Add Label Warning for Hep B Virus Reactivation
January 11, 2017
- Chuikyo to Kick Off Debates to Elaborate Pricing Revamp; 2 Industry Hearing Sessions Planned
January 11, 2017
- “Drug Value Assessments Will Be Critical”; High-Priced Innovative Drugs to Be a Topic at OECD Meeting: Health Minister
January 10, 2017
- MHLW to Regularly Compile Optimal Drug Use Guidelines from FY2017: Pharma Bureau Chief
January 6, 2017
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…